Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Glenmark expects...

    Glenmark expects generics to drive growth over next 3 yrs

    Written by Ruby Khatun Khatun Published On 2017-09-25T10:37:42+05:30  |  Updated On 18 Aug 2021 3:50 PM IST

    Mumbai: Pharma firm Glenmark Pharmaceuticals has said its pipeline of specialty and innovative products over the next three to four years is expected to act as a defense against generics price erosion and competition and will boost profitable growth.


    Over the last few years, the company has invested significantly to mark the step-wise transition from generics to an innovation-driven organization, according to the company's annual report.


    "Our pipeline of specialty products, to be rolled out over the next three to four years, is expected to act as a defense against generics price erosion and increase in competition, and boost profitable growth," Glenmark chairman and managing director Glenn Saldanha said.


    "Over the next three years, generics will continue to fuel our growth. After that, we expect the unlocking of revenues from the specialty/innovation business."


    The next few years will see consistent revenues and profitability without the need for inorganic growth through acquisitions, Saldanha said, adding that specialty and innovative products will comprise 30 percent of its revenues by 2025.


    "Growth will not come at the cost of profits. We anticipate steadily improving our profitability margin from 22 percent - 25 percent by 2025. Our R&D expenses will stay at roughly 11 - 12 percent of revenues," he said.


    The company said that its focus in emerging markets will be to invest in product pipeline in dermatology, respiratory and the oncology therapy and focus on discovering primarily first-in-class molecules globally.


    "Despite the challenging economic situation in most emerging markets including the volatile currencies, we will continue to remain positive on the long-term growth prospects in key emerging markets," the company said.


    The US market will continue to remain the most important market and it will continue to invest significantly, it said.


    All the incremental R&D resources are being invested in the US market and this region will be a key driver for growth in the future.


    The company will also continue with its approach of out-licensing its molecules, the annual report said. Going ahead, the organization will continue to lay equal emphasis on small molecules as well as biologics and will continue to focus on discovering primarily first-in-class molecules globally for unmet medical needs.

    acquisitionscompetitiondrive growthgenericsGlenmarkGlenmark PharmaGlenmark PharmaceuticalsGlenn Saldanhagrowthoncologyprice erosionprofitabilityrevenues
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok